T + A方案改善免疫微环境，实现晚期HCC优质生存
Bevacizumab plus AtezolizumabImprove the Immune Microenvironment and Achieve High Quality Survival of Advanced in HCC
摘要: 人类肝细胞癌(HCC)为全世界第四大肿瘤致死因素，约一半以上的HCC病人被诊断时疾病已经进展到了晚期，缺乏治疗根除的可能性。因此目前临床上晚期肝恶性肿瘤的治疗主要以全身系统性药物治疗为主。IMbrAve150研究揭示了抗血管形成药贝伐珠单抗(bevacizumab，BEVA，简称T) + 免疫检测点PD-1抑制剂阿替利珠单抗(atezolizumab，ATEZO，简称A)的T + A方法在不能直接手术切除且未进行系统处理的肝癌病人中，明显高于索拉非尼的总生存期(Overall Survival, OS)及无进展生存期(Progression free Survival, PFS)，增加客观应答率(Objective Response Rate, ORR)，显著延长中位生存期(Median Survival Time, MST)、明显改善患者生活质量(Quality of Life, QoL)。本文就联合治疗对晚期肝癌的获益作一综述。
Abstract: Human hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death in the world. About half of HCC patients develop to advanced stage after diagnosis and have lost the chance of surgical eradication. Therefore, the current clinical treatment of advanced liver cancer is mainly based on systemic drug therapy. The IMbrAve150 study revealed that the antiangiogenic drug bevacizumab (BEVA, T) plus the immunodetection point PD-1 inhibitor atezolizumab (ATEZO, A) T + A method was significantly better than sorafenib in Overall Survival (OS) and progression-free sur-vival (PFS) in patients with liver cancer that cannot be resected directly without systematic treat-ment free Survival (PFS), increased Objective Response Rate (ORR), significantly prolonged Median Survival Time (MST), and obviously improved the Quality of life of patients Life, (QoL). This article reviews the benefits of combination therapy for advanced in liver cancer.
文章引用：阿力亚·买买提吐尔逊, 张韬. T + A方案改善免疫微环境，实现晚期HCC优质生存[J]. 临床医学进展, 2023, 13(3): 4867-4873. https://doi.org/10.12677/ACM.2023.133695

参考文献

[1] Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[2] Renne, S.L., Sarcognato, S., Sacchi, D., et al. (2021) Hepatocellular Car-cinoma: A Clinical and Pathological Overview. Pathologica, 113, 203-217. [Google Scholar] [CrossRef] 
[3] Zhang, W., He, H., Zang, M., et al. (2017) Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma. Gastroenterology, 153, 249-262. [Google Scholar] [CrossRef] [PubMed]
[4] Altekruse, S.F., Henley, S.J., Cucinelli, J.E. and McGlynn, K.A. (2014) Changing Hepatocellular Carcinoma Incidence and Liver Cancer Mortality Rates in the United States. American Journal of Gastroenterology, 109, 542-553. [Google Scholar] [CrossRef] [PubMed]
[5] Xu, L., Kim, Y., Spolverato, G., Gani, F. and Pawlik, T.M. (2016) Racial Disparities in Treatment and Survival of Patients with Hepatocellular Carcinoma in the United States. Hepatobiliary Sur-gery and Nutrition, 5, 43-52. [Google Scholar] [CrossRef] [PubMed]
[6] Zhang, G., Li, R., Deng, Y. and Zhao, L. (2018) Conditional Sur-vival of Patients with Hepatocellular Carcinoma: Results from the Surveillance, Epidemiology, and End Results Registry. Expert Review of Gastroenterology & Hepatology, 12, 515-523. [Google Scholar] [CrossRef] [PubMed]
[7] Cheng, A.-L., Kang, Y.-K., Chen, Z., et al. (2009) Efficacy and Safety of Sorafenib in Patients in the Asia-Pacific Region with Advanced Hepatocellular Carcinoma: A Phase III Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet Oncology, 10, 25-34. [Google Scholar] [CrossRef] 
[8] Kudo, M., Finn, R.S., Qin, S., et al. (2018) Lenvatinib ver-sus Sorafenib in First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial. Lancet, 391, 1163-1173. [Google Scholar] [CrossRef] 
[9] Bruix, J., Qin, S., Merle, P., et al. (2017) Regorafenib for Patients with Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment (RESORCE): A Randomised, Dou-ble-Blind, Placebo-Controlled, Phase 3 Trial. Lancet, 389, 56-66. [Google Scholar] [CrossRef] 
[10] Abou-Alfa, G.K., Meyer, T., Cheng, A.L., et al. (2018) Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. New England Journal of Medicine, 379, 54-63. [Google Scholar] [CrossRef] 
[11] Zhu, A.X., Kang, Y.K., Yen, C.J., et al. (2019) Ramu-cirumab after Sorafenib in Patients with Advanced Hepatocellular Carcinoma and Increased α-Fetoprotein Concentrations (REACH-2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 20, 282-296. [Google Scholar] [CrossRef] 
[12] Finn, R.S., Qin, S., Ikeda, M., et al. (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine, 382, 1894-1905. [Google Scholar] [CrossRef] 
[13] Hinshaw, D.C. and Shevde, L.A. (2019) The Tumor Microenvi-ronment Innately Modulates Cancer Progression. Cancer Research, 79, 4557-4566. [Google Scholar] [CrossRef] 
[14] Kudo, M. (2019) Immuno-Oncology Therapy for Hepato-cellular Carcinoma: Current Status and Ongoing Trials. Liver Cancer, 8, 221-238. [Google Scholar] [CrossRef] [PubMed]
[15] Gao, B., Jeong, W.-I. and Tian, Z. (2008) Liver: An Organ with Predomi-nant Innate Immunity. Hepatology, 47, 729-736. [Google Scholar] [CrossRef] [PubMed]
[16] Gao, Q., Wang, X.-Y., Qiu, S.J., et al. (2009) Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma. Clinical Cancer Research, 15, 971-979. [Google Scholar] [CrossRef] 
[17] Steel, J.L., Geller, D.A., Gamblin, T.C., et al. (2007) De-pression, Immunity, and Survival in Patients with Hepatobiliary Carcinoma. Journal of Clinical Oncology, 25, 2397-2405. [Google Scholar] [CrossRef] 
[18] Calderaro, J., Rousseau, B., Amaddeo, G., et al. (2016) Pro-grammed Death Ligand 1 Expression in Hepatocellular Carcinoma: Relationship with Clinical and Pathological Features. Hepatology, 64, 2038-2046. [Google Scholar] [CrossRef] [PubMed]
[19] Takada, K., Okamoto, T., Shoji, F., et al. (2016) Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma. Journal of Thoracic Oncology, 11, 1879-1890. [Google Scholar] [CrossRef] [PubMed]
[20] Benson, A.B., D’Angelica, M.I., Abbott, D.E., et al. (2017) NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. Journal of the National Comprehensive Cancer Network, 15, 563-573. [Google Scholar] [CrossRef] [PubMed]
[21] Gevensleben, H., Dietrich, D., Golletz, C., et al. (2016) The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. Clinical Cancer Research, 22, 1969-1977. [Google Scholar] [CrossRef] 
[22] Yokoyama, S., Miyoshi, H., Nakashima, K., et al. (2016) Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma. Clinical Cancer Research, 22, 4727-4734. [Google Scholar] [CrossRef] 
[23] Jelic, S. and Sotiropoulos, G.C. (2010) Hepatocellular Car-cinoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Annals of Oncology, 21, 59-64. [Google Scholar] [CrossRef] [PubMed]
[24] Kane, R.C., Farrell, A.T., Madabushi, R., et al. (2009) Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma. Oncologist, 14, 95-100. [Google Scholar] [CrossRef] [PubMed]
[25] Bruix, J., Raoul, J.-L., Sherman, M., et al. (2012) Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma: Subanalyses of a Phase III Trial. Journal of Hepatology, 57, 821-829. [Google Scholar] [CrossRef] [PubMed]
[26] Lee, H.W., Cho, K.J. and Park, J.Y. (2020) Current Status and Fu-ture Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest? Immune Network, 20, e11. [Google Scholar] [CrossRef] [PubMed]
[27] Yin, Z. and Li, X. (2020) Immunotherapy for Hepatocellular Carcino-ma. Cancer Letters, 470, 8-17. [Google Scholar] [CrossRef] [PubMed]
[28] Sangro, B., Chan, S.L., Meyer, T., et al. (2020) Diagnosis and Management of Toxicities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Journal of Hepatology, 72, 320-341. [Google Scholar] [CrossRef] [PubMed]
[29] Rahma, O.E. and Hodi, F.S. (2019) The Intersection be-tween Tumor Angiogenesis and Immune Suppression. Clinical Cancer Research, 25, 5449-5457. [Google Scholar] [CrossRef] 
[30] Roche, H.-L. (2021) A Study of the Safety and Efficacy of Atezolizumab Administered in Combination with Bevacizumab and/or Other Treatments in Participants with Solid Tu-mors.
https://clinicaltrials.gov/ct2/show/NCT02715531
[31] Lee, M.S., Ryoo, B.Y., Hsu, C.H., et al. (2020) Ate-zolizumab with or without Bevacizumab in Unresectable Hepatocellular Carcinoma (GO30140): An Open-Label, Multi-centre, Phase 1b Study. The Lancet Oncology, 21, 808-820. [Google Scholar] [CrossRef] 
[32] Kelley, R.K. (2020) Atezolizumab plus Bevacizumab—A Landmark in Liver Cancer. New England Journal of Medicine, 382, 1953-1955. [Google Scholar] [CrossRef] 

为你推荐